Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Files

717780.pdf (827.64 KB)

Document type

Article

Version

Published version

Publication date

2021-11-01

All rights reserved

Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/183451

ICH Q12: innovadora y controvertida (parte 2)

Journal Title

Authors

Director/Tutor

Journal ISSN

Volume Title

Related resource

Abstract

This work has been published in two parts. In the first, the conceptual framework of the ICH and more specifically of the ICH Q12 was reviewed. In this second, and last, the regulatory and enabling tools of the ICH Q12 are reviewed, which is complemented by a practical part or 'survey' carried out with some professionals in the pharmaceutical industry, although the sample is very small and cannot be generalized, It is important to realize that more information and training on it is necessary at this time for its effective application.

Subject

Tecnologia farmacèutica, Comprimits (Medicina), Desenvolupament de medicaments

Subject (English)

Pharmaceutical technology, Tablets (Medicine), Drug development

Citation

Collections

Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)

Citation

MONSONÍS CENTELLES, Laura and GARCÍA MONTOYA, Encarna. ICH Q12: innovadora y controvertida (parte 2). Pharmatech. 2021. Vol. 60, num. 80-91. ISSN 2340-2105. [consulted: 15 of August of 2026]. Available at: https://hdl.handle.net/2445/183451

Export metadata

JSON - METS

Share record